Cell-identity switches, in which terminally differentiated cells are converted into different cell types when stressed, represent a widespread regenerative strategy in animals, yet they are poorly documented in mammals. In mice, some glucagon-producing pancreatic α-cells and somatostatin-producing δ-cells become insulin-expressing cells after the ablation of insulin-secreting β-cells, thus promoting diabetes recovery. Whether human islets also display this plasticity, especially in diabetic conditions, remains unknown. Here we show that islet non-β-cells, namely α-cells and pancreatic polypeptide (PPY)-producing γ-cells, obtained from deceased non-diabetic or diabetic human donors, can be lineagetraced and reprogrammed by the transcription factors PDX1 and MAFA to produce and secrete insulin in response to glucose. When transplanted into diabetic mice, converted human α-cells reverse diabetes and continue to produce insulin even after six months. Notably, insulin-producing α-cells maintain expression of α-cell markers, as seen by deep transcriptomic and proteomic characterization. These observations provide conceptual evidence and a molecular framework for a mechanistic understanding of in situ cell plasticity as a treatment for diabetes and other degenerative diseases.
Fostering cell regeneration in damaged tissue is one of the cornerstones of regenerative medicine. Attempts to reprogram human fibroblasts, keratinocytes or pancreatic exocrine cells towards insulin production have been unsatisfactory [1] [2] [3] [4] . In diabetic mice, insulin-producing cells are naturally reconstituted by consistent but rare islet cell-type interconversion events [5] [6] [7] . In human islets, bihormonal cells have been described under certain conditions in vitro 8, 9 and in patients with diabetes [10] [11] [12] . This is compatible with the existence of adaptive cell identity changes that must be confirmed and understood to harness their regenerative potential in diabetes 8, [13] [14] [15] . These claims remain speculative without evidence based on cell-tracing analyses 16, 17 .
PDX1 and MAFA are required for β-cell development, maturation and function 18 . We and others have previously shown that the overexpression of these transcription factors convert embryonic or adult α-cells of diabetic mice into insulin-producers 13, 19 . Here we show that human αand γ-cells may become glucose-dependent insulin secretors.
Generation of human monotypic pseudoislets
We devised a multistep approach to study islet cell plasticity: (1) cell sorting by flow cytometry using cell-surface antibodies 20 ; (2) adenoviral green fluorescent protein (Ad-GFP) labelling of purified islet cells expressing PDX1, MAFA and/or NKX6-1; (3) reaggregation of labelled cells into monotypic 'pseudoislets' (that is, islet-like 3D-clusters containing only one islet cell-type); and (4) in vitro and in vivo functional, molecular profiling, and immunogenicity analyses ( Fig. 1a ).
Cell purity after sorting was 99% for αand β-cells, and 94% for γ-cells, whereas δ-cell purification was unreliable with available antibodies (Extended Data Fig. 1a-c ; Supplementary Tables 1 and 2) . Purified islet cells were transduced with different transcription factors and GFP (more than 99% efficiency; Extended Data Fig. 1d ), allowing a traceability equivalent to genetic cell-lineage analyses in mice.
Because dissociated single β-cells fail to secrete insulin in vitro 21 , we validated the experimental approach by assessing the secretory function of monotypic pseudoislets of β-cells. We reaggregated the GFP-labelled β-cells either alone or with human mesenchymal stem cells (MSCs) and human umbilical vein endothelial cells (HUVECs), to recreate a beneficial niche for cell function 22, 23 (Extended Data Fig. 2a, b ). β-cell pseudoislets formed within a day in the presence of HUVECs and MSCs (hereafter termed HM cells) (Extended Data Fig. 2a, c) . β-cell pseudoislets showed rare apoptosis and restored glucose-stimulated insulin secretion (GSIS), comparable to that of native islets (Extended Data Fig. 2d -g). The absence of α-, δand γ-cells in monotypic β-cell pseudoislets did not affect GSIS ex vivo. Thus, simple reaggregation invigorates the purified human β-cells, probably by reconstituting an islet-like environment 24 .
Insulin secretion by transduced human α-cells
Pdx1, Mafa and Nkx6-1 are β-cell-enriched transcription factors that are spontaneously upregulated in insulin-producing α-cells after total β-cell ablation in mice 6 . We thus explored whether human non-β-cells acquire insulin production after ectopic expression of these factors. We transduced purified human α-cells with bicistronic adenoviral vectors expressing a mouse β-cell transcription factor (Pdx1, Mafa and Nkx6-1) along with GFP, before pseudoislet reaggregation and analysis (1 week later; Fig. 1a, b) .
Control GFP-transduced α-cells (αGFP pseudoislets) were insulinnegative (99.4 ± 0.4% (mean ± s.d.)), whereas the combination of PDX1 and MAFA (αPM pseudoislets) triggered the highest reprogramming efficiency (38.3 ± 5.0%; Fig. 1c, d ; Extended Data Fig. 3a, b ).
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After 7 days of culture, nearly all insulin-producing α-cells maintained expression of GCG and ARX (Fig. 1d ; Extended Data Fig. 3c, d ; see below the RNA profiling). αPM cells cultured as single cells displayed a much lower reprogramming frequency (3.9%) ex vivo or in vivo after transplantation ( Fig. 1e ; Extended Data Fig. 3e ; data not shown). Similar to β-cells, α-cells aggregated faster into pseudoislets in the presence of HM cells (+HM), although reprogramming frequency remained unchanged ( Fig. 1e and Extended Data Fig. 3f-h ). Apoptosis and proliferation were rare (Extended Data Fig. 3i, j) . Both αPM and αPM + HM pseudoislets displayed significant GSIS in culture ( Fig. 1f) , with HM cells further enhancing secretion. Therefore, coexpression of Pdx1 and Mafa engages human α-cells into glucose-dependent insulin secretion.
Insulin secretion by transduced human γ-cells
We observed that PPY-producing γ-cells transduced with PDX1 and MAFA engage in insulin production as efficiently as α-cells, while maintaining PPY expression (Extended Data Fig. 4a-d ). HM cells accelerated reaggregation, yet decreased reprogramming frequency (Extended Data Fig. 4e-g) . γPM pseudoislets secreted insulin after glucose stimulation, even better than α-cells ( Fig. 1f ; Extended Data Fig. 4h ). This is the first observation of γ-cell plasticity. Combined, these observations represent the first, to our knowledge, direct evidence for the plasticity of mature human islet non-β-cells.
Diabetes remission by insulin-secreting α-cells
Pseudoislets maintained in culture lose cells steadily, yet levels of insulin mRNA increase (Extended Data Fig. 4i, j) . This suggests that culture conditions are not optimal but reprogramming nevertheless progresses with time. To evaluate pseudoislet function in vivo, we transferred pseudoislets made of αPM + HM cells (referred to as αPM pseudoislets hereafter) into immunodeficient non-obese diabetic (NOD)/ severe combined immunodeficient (SCID)/Il2rg −/− (NSG) mice, in five different experiments ( Fig. 2a ; Supplementary Table 3 ). α-cells from non-diabetic donors were transplanted into healthy (experiment (exp.) 1; Extended Data We detected circulating levels of human insulin after glucose stimulation in healthy mice given αPM pseudoislets from non-diabetic donors (exp. 1; Extended Data Fig. 5a, b ; Supplementary Table 4 ), and then tested whether the insulin-producing human α-cells ameliorate the clinical signs of the diabetic mice. Glucose tolerance and GSIS were improved in mice receiving the maximum amount of αPM pseudoislets that we could generate from a single donor (between 200 and 1,000) (exp. 2; Extended Data Fig. 6a -k; Supplementary Table 5 ). Yet hyperglycaemia was not normalized, probably owing to the suboptimal quantity of engrafted pseudoislets. We therefore transplanted αPM pseudoislets from several non-diabetic-donors (exp. 3: 6,000 αPM pseudoislets from 6 donors, and exp.4: 4,000 αPM pseudoislets from 3 donors; Fig. 2a -c, Supplementary Table 6 ). Diabetic mice became normoglycaemic ( Fig. 2b , c) and body weight loss was curbed, like controls receiving intact islets (4,000 islet equivalents; Extended Data Fig. 6l ). Glucose tolerance and GSIS were similar in mice transplanted with either reprogrammed α-cells or intact islets ( Fig. 2d ; Extended Data Fig. 6m , n). Hyperglycaemia reappeared after graft removal, proving that recovery was induced by the engrafted insulin-secreting human αPM.
Although αGFP pseudoislet grafts did not display insulin production (<1%; Extended Data Fig. 5c , exp. 1), most α-cells in αPM grafts contained insulin (67.9 ± 1.9%; Fig. 2f , g) and became monohormonal (91.7 ± 9.7%; Fig. 2f , h), indicating that the in vivo environment fosters cell conversion and maturation (exp. 1: Extended Data Fig. 5d -g). Transplanted αPM pseudoislets were vascularized and innervated (Extended Data Figs. 5e, 6o), which correlates with their functionality, without cell proliferation (Extended Data Fig. 6p ). They contained abundant cells that coexpressed GFP and insulin for up to 6 monthsthe longest period analysed (68.4% reprogramming efficiency; Fig. 2i , exp. 2; Extended Data Fig. 6q , r). In summary, insulin-producing human α-cells retain their phenotype in vivo, restoring normoglycaemia in diabetic mice.
α-cells from patients with T2D display distinctive transcriptomic signatures 25 . We then explored whether T2D α-cells can engage in regulated insulin secretion in culture and in vivo (exp. 5; Extended Data Fig. 7 and Supplementary Table 7 ). In transplanted mice, random-fed blood glucose levels were decreased, with complete recovery when the mice were given anti-glucagon therapy 26, 27 to compensate for the insufficient number of transplanted cells (Extended Data Fig. 7e -g). We also Ad-GFP α-cell pseudoislet (culture day 7)
Ad-PDX1+MAFA Table 2 ). Labelled islet cells were reaggregated into pseudoislets and analysed in vitro and in vivo after transplantation into immunodeficient mice to examine their functionality, molecular profiling and immunogenicity. TF, transcription factor. b, Live imaging during reaggregation of GFPtransduced α-cells. c, Insulin protein expression in α-cells 7 days after transduction and aggregation. MN6, MAFA + NKX6-1; PM, PDX1 + MAFA; PN6, PDX1 + NKX6-1; 3TFs, PDX1 + MAFA + NKX6-1. ****P < 0.0001 versus GFP control; †P = 0.047, † † † †P < 0.0001 versus PM, one-way analysis of variance (ANOVA) with Tukey's multiple comparisons test. n = 10 (GFP, PM), n = 5 (PDX1, 3TFs), n = 3 (MAFA, NKX6-1, MN6 and PN6). All samples are replications from different donors. d, Immunofluorescence of two pseudoislets made of α-cells transduced with GFP (αGFP) or GFP and PDX1 + MAFA (αPM) (see Extended Data Fig. 3a ). Most reprogrammed insulin-producing α-cells express glucagon 1 week after transduction. e, Reaggregation significantly increases insulin expression in αPM cells. Only 4% of αPM cells contain insulin if kept as single α-cells. After reaggregation, either alone or in combination with HUVECs and MSCs (HM), 35% become insulinpositive. NS, not significant (P = 0.38 αGFP singlets versus αPM singlets; P = 0.40 αPM versus αPM + HM); ****P < 0.0001, one-way ANOVA with Tukey's multiple comparisons test. n = 3 donor samples in each condition. f, GSIS. C-peptide release from αPM cells is enhanced in the presence of HM cells; the dotted line indicates C-peptide background level (detection limit). *P = 0.028, **P = 0.0068, ****P < 0.0001, two-way repeated-measures ANOVA with Holm-Sidak's multiple comparisons test. n = 5 donor samples in each condition. Scale bars, 25 μm. Images are representative of 5 (b) or 38 (d) independent experiments. Data are mean ± s.e.m. observed improved glucose tolerance and GSIS ( Fig. 2e and Extended Data Fig. 7h -j). Notably, the engrafted T2D αPM pseudoislets retained expression of ARX, and endogenous PDX1, MAFA and NKX6-1 were upregulated (Extended Data Fig. 7o ). At the ultrastructural level, T2D αPM cells contained β-like dense-core granules (Extended Data Fig. 7p ). Apoptotic cells were rare (Extended Data Fig. 7q ). In conclusion, human α-cells in T2D conditions preserve the plasticity potential.
Hybrid signature of modified α-cells
To characterize the insulin-producing α-cells ( Fig. 1 ), we performed bulk RNA-seq on sorted αand β-cells, on αGFP, αPM and βGFP pseudoislets after 7 days of culture, and on grafted αPM pseudoislets 1 month after transplantation (Supplementary Table 8 ). Principal component and correlation analyses revealed that αPM cells display a signature that is intermediate between αand β-cells, further shifted towards that of β-cells after transplantation into mice ( Fig. 3a, b ).
To identify α-cell identity changes linked to the acquisition of the β-cell phenotype, we focused on differentially expressed genes (DEGs) between sorted αand β-cells. In total, 587 DEGs were more abundant in sorted β-cells than in α-cells; we termed these 'β-cell-related' genes ( Fig. 3c , Supplementary Table 10 ) and measured how they were modulated in α-cells after aggregation or coexpression of PDX1 and MAFA (aggregation or PM effect, respectively). Cell aggregation led to the upregulation in α-cells of 128 β-related genes (out of 587) ( Fig. 3d ; Supplementary Table 11 ), indicating that mere aggregation is sufficient to impose functional aspects of the β-cell signature. Some of the upregulated genes are crucial to β-cell function, such as ABCC8 (also known as SUR1), ENTPD3 28 , SYT13 29 and UCHL1 30 . Similarly, other gene sets involved in β-cell function, such as those involved in mitochondrial metabolism, were upregulated, whereas genes involved stress or inflammatory signalling pathways were downregulated after α-cell aggregation (Extended Data Fig. 8a -c).
To determine the effect of PDX1 and MAFA coexpression on α-cell reprogramming, we compared αGFP and αPM pseudoislets. There were 115 upregulated β-related genes in αPM, comprising important functional β-cell markers such as INS, MAFA (endogenous), PSCK1, ADCYAP1 31 , PFKFB2 32 , RBP1 33 and SIX3 34 ( Fig. 3e ; Supplementary  Table 12 ). Finally, we evaluated the overall effect of combined aggregation and the PDX1 and MAFA effect by comparing αPM pseudoislets with sorted α-cells: in this comparison, 268 β-related genes were upregulated in αPM pseudoislets, including IAPP and GLP1R ( Fig. 3f ; Supplementary Table 13 ). Gene sets such as 'hallmark β-cells' and 'regulation of insulin secretion' were also enriched ( Fig. 3g ; Extended Data Fig. 8d ). Moreover, some α-cell-enriched genes were downregulated (Extended Data Fig. 8e -h; Supplementary Tables 14-17), whereas others were enhanced. These contrasting changes in α-identity genes suggest the existence of a simultaneous ongoing refractory response to fate conversion 35 ( Supplementary Table 18 ). Consistent with this, the expression of ARX remained invariable in reprogrammed α-cells, incidentally confirming that GSIS is compatible with ARX activity (Extended Data Fig. 3d ).
Global proteomic analyses confirmed that many of the upregulated β-cell-related genes were also upregulated as proteins. In total, 33 β-cell-related proteins were detected in α-cells after aggregation, Grafts were removed after 4 weeks or up to 24 weeks in the longest experiment. ipGTT, intraperitoneal glucose tolerance test. b, Randomfed blood glucose levels in experiment 3. Nx, graft removal. Glycaemia was decreased to normal levels (dotted lines) after engraftment of 6,000 pseudoislets generated from 6 donors (red line), in 3 transplantations (Tx; 2,150 + 3,100 + 750), similar to controls receiving human islets (4,000 islet equivalents, blue lines). Untransplanted diabetics remained hyperglycaemic (black lines). n = 5 (DT + noGraft), n = 3 from 3 donors (DT + islets), n = 1 from 6 donors (DT + αPM), n = 5 mice (noDT + noGraft). c, Random-fed blood glucose levels in experiment 4. In total, 4,000 pseudoislets from 3 donors were transplanted, leading to complete rescue. n = 3 (DT + noGraft), n = 2 from 2 donors (DT + islets), n = Article reSeArcH PDX1 and MAFA coexpression, or both ( Fig. 3d -f, h). Most (30 out of 33) were more abundant in αPM pseudoislets than in αGFP pseudoislets. Several functional β-cell proteins were upregulated, such as INS, PCSK1, PFKFB2, RBP1, ADCYAP1, UCHL1, ABCC8, ENTPD3 and IAPP ( Fig. 3h ; Supplementary Table 19 ). Notably, the protein hierarchical clustering grouped the αPM pseudoislets with βGFP pseudoislets, underscoring the phenotypic shift (Extended Data Fig. 8i ).
We also performed RNA-seq on five different αPM grafts obtained 1 month after transplantation ( Supplementary Table 8 ). Compared to αPM pseudoislets before transplantation, β-cell markers such as IGF2, MEG3 and GLRA1 and pathways related to 'hormone synthesis' , 'secretion' and 'innervation' were further upregulated (Extended Data Fig. 8j ; Supplementary Table 20 ). These observations are compatible with the immunofluorescence results, the highly functional phenotype after transplantation ( Fig. 2b-h) , and the sympathetic innervation of αPM pseudoislets (Extended Data Fig. 6o ).
Combined transcriptomic and proteomic analyses indicate that aggregation drives the upregulation of functional β-cell markers. Subsequent PDX1 and MAFA expression further induces additional β-cell genes, leading to GSIS acquisition (Extended Data Fig. 8k ).
From glucagon to insulin secretion
To dissect the reprogramming process at single-cell resolution, we performed single-cell RNA sequencing (scRNA-seq; Extended Data Fig. 9a ). We analysed αGFP, βGFP and αPM pseudoislets cultured for 1 week. Three distinct αGFP, αPM and βGFP cell populations were discovered using t-distributed stochastic neighbour embedding (t-SNE) visualization ( Fig. 4a ). Most cells in the αPM cluster were INS and GCG bihormonal, with little heterogeneity (Extended Data Fig. 9b ).
Using the pseudotemporal ordering 36 algorithm, we reconstructed the sequence of gene expression profiles and the evolution of each cell without previous knowledge of the genes that define progression (Extended Data Fig. 9a ). We found one main path, with few minor branches, enabling the allocation of three pseudotime-dependent progression states for αPM cells: early, mid and late ( Fig. 4b ; Extended Data Fig. 9c, d ).
β-cell-related genes were upregulated in late cells (INS, UCHL1 and PCSK1; Fig. 4c -e), whereas many α-cell-related genes were downregulated (GCG and TM4SF4). Several of these genes were not previously detected by bulk RNA-seq (for example, β-cell genes such as HIST3H2A, NEFL, NPTX2 and SUSD4, and the α-cell genes FAP, EGFL7 and USH1C). Some α/β-cell-related genes were not modulated after pseudotime progression (ARX; Extended Data Fig. 9g ), whereas others changed in the opposite direction (NR4A2; Fig. 4c ). This confirms the persistence of some resistance to reprogramming, and this was also observed by bulk RNA-seq and in mouse studies 35 .
When superimposing pseudotime categories on cells in t-SNE mapping, we found a pseudotemporal transition along the α-to-β-cell progression (Fig. 4f ). Collectively, this suggests that most α-cells in αPM pseudoislets engage as INS-expressing cells, without alternative cell-fate allocations. Therefore, human α-cells are suited to direct reprogramming.
Signalling pathway analyses also revealed changes in the different reprogramming stages: oxidative phosphorylation was more active in late than in early cells, and RICTOR was downregulated as an upstream regulator ( Supplementary Table 21 ). Notably, opposite changes (that is, impaired oxidative phosphorylation and activated RICTOR) have recently been linked to β-cell dedifferentiation during β-cell failure 37 . This suggests that human reprogrammed α-cells are healthy and different from T2D-diseased β-cells.
Insulin-secreting α-cells are hypoimmunogenic
The hybrid character of human insulin-producing α-cells, with their curative properties when transplanted to diabetic mice yet maintaining a robust α-cell identity, led us to inquire whether they would be autoimmune targets in type 1 diabetes (T1D). We performed cytotoxic T lymphocyte (CTL) killing assays using HLA-A2-restricted β-cell-specific CD8 + T cell clones derived from patients with recent T1D onset 38, 39 (Extended Data Fig. 10a ). As target cells, βGFP, αGFP and αPM pseudoislets devoid of HM cells were generated from seven different HLA-A2 haplotype donors ( Supplementary Table 22 ). We validated the specificities and cytotoxic properties of effector cells (CTL clones) in each independent experiment (Extended Data Fig. 10b , c) and on β-cells obtained from βGFP pseudoislets. Preproinsulin (PPI)-directed CTLs killed βGFP cells 39 , yet the stressed β-cell-specific anti-defective ribosomal product (DRiP) CTLs did not, indicating that β-cells in pseudoislets are not endoplasmic reticulum (ER) stressed and have no erroneous INS mRNA translation 38 (Fig. 5a ). This contrasts with studies reporting that up to 40% of β-cells from dispersed human islets are lysed by DRiP CTLs 38 , and suggests that pseudoislets confer protection against ER stress. Glucagon-producing α-cells were killed by the β-cell-specific anti-PPI and anti-DRiP CTLs only if loaded with their cognate PPI or DRiP peptide epitopes (Fig. 5b) , which confirms the specificity of CTLs. Insulin-producing α-cells were sensitive to PPI-directed CTLs, similar to β-cells, but not to DRiP-specific T cells ( Fig. 5c ), suggesting that αPM cells are less stressed than dispersed β-cells 38 . When loaded with PPI or DRiP peptide epitopes, αPM cells were more sensitive to the respective CTLs, but with lower death rates than PPI-loaded αGFPs.
In conclusion, glucose-responsive insulin-secreting human reprogrammed α-cells display reduced immunogenicity for T1D autoreactive T cells. Modified α-cells produce and process insulin, and present its leader or signal peptide on their surface, like native β-cells.
The intrinsic β-cell processing steps are operative, but seem to be less prone to ER stress and translational errors than in native β-cells.
Discussion
Breakthroughs in islet cell biology have revealed that cell identity and maturity are flexible states. Here we provide conceptual evidence for human islet plasticity, given applicability concerns of mouse data to the clinic 40 . It remains to be seen if diabetes therapies that modulate islet cell-type interconversion without side effects are possible via the targeted delivery of transcription factors into islets, or pharmacologically. The streamlined culture system described here should allow the identification of a gene set required to confer GSIS to islet non-β-cells, perhaps involving small-molecule screening such as that adapted for β-like cells differentiated from human pluripotent-cells.
The human fetal β-cell line EndoC-βH1 42 , human embryonic stemcell-derived surrogate β-cells 41 , and reprogrammed mouse α-cells 13 are also hypoimmunogenic. Future studies should involve testing the immunogenicity of modified α-cells in humanized mice modelling responses towards islet grafts in vivo.
We did not analyse human δ-cells, but in addition to human αand γ-cells, PDX1 and MAFA also reprogram mouse δ-cells (data not shown). Notably, NKX6-1 seems dispensable for reprogramming, but might be required for deeper β-cell-like maturation 43 . Combined, this islet non-β-cell plasticity leads to a strategic paradigm shift from an α-cell-specific to a broader islet-specific targeting approach in vivo. Notably, islet non-β-cells (1) are developmentally and epigenetically close to β-cells 8, 44 ; (2) occupy the same environmental niche; (3) spontaneously engage in insulin production 6,7 more rapidly and efficiently than other cell types [1] [2] [3] [4] 45 , even under disease conditions (α-cells from T2D donors); and (4) are abundant in patients with type and 1 and 2 diabetes. In addition, a massive α-cell loss has no major physiological effect 26, 46 . For these reasons, islet non-β-cells are optimal targets for β-cell regeneration. The development of islet cell-type interconversion therapies may indicate that insulin-producing cells are replenished without the need for remaining β-cells, ex vivo embryonic stem cell or induced pluripotent stem cell differentiation, or other invasive procedures.
Beyond diabetes, the adaptive cell identity changes are likely to be a feature of different cell types in many organs. Therefore, reconstitution of missing cell populations by fostering the innate in situ adaptive cell plasticity arises as a promising prospective to treat degenerative diseases. 5  10  20  5  10  20  5  10  20  5  10  20  5  10  20  5  10  20  5  10  20  5  10  20  5  10  20  5  10  20  5  10  20  5 10 20 Supplementary Table 22 for sample information.
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MEthodS
Human samples. All studies involving human samples were approved by ethical committee in University of Geneva. Human pancreatic islets were obtained from ECIT program (University Hospital of Geneva or Diabetes Research Institute in Milan) or the NIDDK-funded Integrated Islets Distribution Program (IIDP) at City of Hope. Subject details are described in Supplementary Table 1 . The number of islets was determined by material availability, especially in T2D donor samples. Certified HUVECs and human bone-marrow-derived MSCs were purchased from Lonza (catalogue no. C2519A, PT-2501) and cultured according to manufacturer's instructions. Mycoplasma contamination was also checked. Isolation of human islet cell-types. Dissociation of human islets and staining with cell-surface antibodies were described previously 8, 20 . Stained cells were sorted on a FACSAria2 (BD Biosciences) or Moflo Astrios (Beckman Coulter) system. Single viable islet cells were gated by forward scatter, side scatter and pulse-width parameters and by negative staining for DAPI (D1306, Invitrogen) or DRAQ7 (B25595, BD Biosciences) to remove doublets and dead cells. Purity of sorted cells. For evaluation of cell purity, sorted islet cell fractions were immunostained for insulin, glucagon, somatostatin, pancreatic polypeptide and ghrelin (see Supplementary Data 1-3) . Stained cells were examined with a confocal microscope (Leica TCS SPE). Only batches with high purity (>96% for α/β cells and >90% for γ-cells) were used (see Extended Data Fig. 1b and Supplementary Table 2 ). Evaluation of purity was also performed by quantitative PCR and RNAseq. Purity (Extended Data Fig. 1c ) was calculated as previously reported 8 . Cell labelling. Adenoviral vectors were produced and purified as described previously 47 . Sorted cells were transduced with adenoviral vectors encoding GFP only, Pdx1-IRES-GFP, Mafa-IRES-GFP or Nkx6-1-IRES-GFP or in combination at 37 °C in 5% CO 2 incubator for 12 h. After three washes, cells were resuspended in BN medium: advanced DMEM/F12 (12634-010) supplemented with penicillin/ streptomycin, 10 mM HEPES, 2 mM GlutaMAX (35050-038), 1× B27 (17504044), 1× N2 (17502048, Life Technologies), 10 mM nicotinamide (N0636), and 1 mM N-acetyl-l-cysteine (A9165, Sigma).
Reconstitution of pseudoislets.
For reaggregation into pseudoislets, labelled islet cells (α/β/γ-cells) were seeded on 96-well ultra-low adherent culture plates for 7 days (1,000 cells per well). Every other day culture medium was changed. For reaggregation with HUVECs and MSCs (HM), 400 HUVECs and 100 MSCs were seeded per well together with 1,000 islet cells in mixed culture medium: 50% BN medium and 50% EGM-2 medium (CC-3162, Lonza) at 37 °C in 5% CO 2 incubator. Morphometric analyses of pseudoislets. Seven days after culture, aggregates were handpicked and their diameters were measured using Leica M205FA binocular equipped with a Leica DFC360FX camera. Single islet cell culture. Sorted islet cells were seeded at single-cell density on chamber-slide wells (Sigma) coated Matrigel (356231, Corning) and cultured in BN medium at 37 °C in a 5% CO 2 incubator, and then assayed as described below.
In vitro time-lapse imaging. For live imaging of cultured cells, images of cultured cells in plate-wells were captured manually at indicated time-points using Nikon Eclipse TE300 microscope (Nikon). Evaluation for transduction efficiency. One or two weeks after reaggregation culture, pseudoislets were dissociated again into single cells using Accutase (A1110501, Life Technologies) and analysed by FACS to count GFP + cells. Doublets and dead cells were removed as mentioned above.
In vitro glucose-stimulated C-peptide secretion test. Pseudoislets or sizematched native islets were handpicked for each assay replicate and washed by incubation for 30 min at 37 °C in Krebs-Ringer Bicarbonate (KRB) buffer containing no glucose and then equilibrated by incubation for 1 h at 37 °C in basal KRB containing 3 mM glucose (Sigma). Samples were then transferred into fresh KRB containing 3 mM (low) glucose for 1 h followed by incubation for another hour in KRB containing 20 mM (high) glucose at 37 °C. Medium was collected after 1-h incubation at each glucose concentration and stored at −80 °C for subsequent analyses. Human C-peptide concentration was quantified using the human Ultrasensitive C-peptide ELISA kit (10-1141-01, Mercodia). Total RNA extraction and quantitative RT-PCR. For all samples, the total RNA was extracted using the Qiagen RNeasy Micro kit, and treated with RNasefree DNaseΙ (Qiagen). cDNA was synthesized using the QuantiTect Reverse Transcription kit (Qiagen). qPCR reactions and analyses were performed as described previously 6 . Each individual sample was run in triplicate. Expression levels were normalized to RN18S, ACTB or GFP. Primer sequences are shown in Supplementary Table 23 . Intraperitoneal glucose tolerance test (ipGTT) was performed as described 6 . Nephrectomy. For graft removal, the kidney with graft was ligated at the renal hilum using 3-0 silk (B. Braun), and then resected. Removed grafts were processed for analyses. Nephrectomy was also performed in control animals. Anti-glucagon receptor antibody treatment. Treatment with anti-glucagon receptor antibody was as described previously 26 ; the anti-GCGR monoclonal antibody A-9 was generated at Eli-Lilly and Company. The antibody was delivered using a subcutaneous implanted osmotic pump (model 2002, Alzet) containing 3 mg ml −1 of anti-GCGR monoclonal antibody in PBS for 2 weeks. Immunofluorescence analyses. Samples processes for immunofluorescence were performed as described previously 6 . Frozen sections were cut at 10-μm thick. Primary antibodies used were: guinea pig anti-porcine insulin (A0564, DAKO, 1:600), chicken anti-insulin (GW10064F, Sigma, 1:1,000), mouse anti-glucagon (G2654, Sigma, 1:1,000), rabbit anti-glucagon (A0565, DAKO, 1:600), rabbit anti-somatostatin (A0566, DAKO, 1:600), rabbit anti-pancreatic polypeptide (T-4088, PenLabs, 1:750), goat anti-ghrelin (sc-10368, SantaCruz, 1:200), rabbit anti-GFP (Life Technologies, 1:500), chicken anti-GFP (ab-13970, Abcam, 1:500), guinea pig anti-PDX1 (gift from C. Wright, 1:1,000), rabbit anti-MAFA (A300-611A, Bethyl, 1:500), rabbit anti-NKX6-1 (BCBC, 1:400), rabbit anti-pHH3 (06-570, Upstate, 1:500), rabbit anti-CD31 (ab28364, abcam, 1:50), rabbit anti-vimentin (ab92547, abcam, 1:100), rabbit anti-tyrosine hydroxylase (ab152, chemicon, 1:1,000), guinea pig anti-ARX (AB2834, BCBC, 1:100), rabbit anti-synaptophysin (A0010, DAKO, 1:50). Secondary antibodies were coupled to Alexa 405, 488, 568, 647 (Life Technologies), FITC, Cy3, Cy5 (Jackson Immunoresearch), or TRITC (Southern Biotech). Sections were counterstained with DAPI. All sections were examined with a confocal microscope (Leica TCS SPE). In Fig. 2i and Extended Data Fig. 6r , confocal tile-scan images were merged as a maximum projection. TUNEL staining. TUNEL staining was performed to evaluate apoptosis using DeadEnd Fluorometric TUNEL System, according to manufacturer's instructions (G3250, Promega). Electron microscopy. Small portion of engrafted islets were fixed with 2.5% glutaraldehyde and 4% paraformaldehyde in PBS, and processed as described 6 . Morphometric analyses were performed using Philips/FEI Tecnai 20 transmission electron microscope. Global transcriptomics analysis. Preparation of libraries, RNA-seq and the quality controls were performed within the Genomics Core Facility of the University of Geneva. In brief, extracted RNA samples were assessed for the quality by Agilent bioanalyzer before library generation. Reverse transcription and cDNA amplification were performed using the SMARTer Ultra Low RNA kit (Clontech). cDNA libraries were prepared using Nextera XT DNA Sample Preparation kit (Illumina), multiplexed and sequenced on an Illumina HiSeq4000 platform with single-end 110-bp reads. The sequencing quality control was done with FASTQC v.0.11.2, followed by sequence alignment to the human reference genome (hg38) using the TopHat v2.0.13 (default parameters). Biological quality control and summarization were done with the PicardTools v1.80. Finally, 13 million reads per samples in average were used for differential expression analysis. Transcriptomic data analyses. The normalization and differential expression analysis was performed with the R/Bioconductor package TCC v.1.16.0 using DEG elimination strategy 49 . DEGs between sorted αand β-cells were selected (fold change > 2; FDR < 0.05) and their expression levels in the different other comparisons was considered for further analyses. Principal component analysis was performed with the 1,000 most variable genes. The Pearson's correlation coefficients were calculated for log 2 transformed ratios. The output data are displayed graphically as a principal component plot, heatmap, dendrogram, volcano plot or Venn diagram. Pathway analysis. The pathway analyses were performed with GSEA (http:// software.broadinstitute.org/gsea/index.jsp) or ingenuity pathway analysis (IPA, QIAGEN, http://www.qiagen.com/ingenuity). Gene sets with significant enrichment in GSEA were identified among C1, C2 or C5 of Molecular Signatures Database v6.0; 'hallmark pancreas beta cell' (http://software.broadinstitute.org/ gsea/msigdb/cards/hallmark_pancreas_beta_cells.html) and 'reactome regulation of insulin secretion' (www.reactome.org/content/detail/422356) in Fig. 3g , 'GO oxidative phosphorylation' (GO:0006119) and 'GO respiratory chain' (GO:0070469) in Extended Data Fig. 8a, b . IPA were performed with the following settings:
Article reSeArcH expression value type (exp log ration), reference set (ingenuity knowledge base), relationships to consider (direct and indirect relationships), interaction networks (70 molecules/network; 25 networks/analysis or 30 molecules/network; 25 or 10 network/analysis), data source (all), confidence (experimentally observed), species (human, mouse, rat), tissue and cell lines (all), mutations (all). Cell lysis and protein digestion. Cells were washed in DPBS and lysed in buffer containing 4% SDS, and boiled at 95 °C for 7 min on a shaker, and sonicated (three rounds at 30 s, 30% power). The protein concentration was determined using a BCA protein assay kit. Samples were pooled ( Supplementary Table 12 ), and dry aliquots containing an estimated amount of 50 μg of proteins were further processed using Filter-Aided Sample Preparation 50 , and desalted using C18 Oasis Elution plates. TMT 11-plex labelling. TMT reagents were re-suspended in acetonitrile (ACN). Desalted peptides were re-suspended in 50 μl of 200 mM EPPS pH 8.5, 15 μl of ACN, and 5 μl of the TMT reagents were added to the respective peptide samples, gently vortexed, and incubated for 1.5 h at room temperature. To prevent unwanted labelling, the reaction was quenched by adding 5 μl of 5% hydroxylamine and incubated for 15 min at room temperature. Equal amounts of the TMT-labelled samples were combined and concentrated to near dryness, followed by desalting via C18 solid phase extraction and passage over a Pierce detergent removal spin column (Thermo Fisher Scientific). Global proteomics analysis: off-line basic pH reversed phase fractionation. The combined labelled peptide samples were pre-fractionated by basic pH reversed phase HPLC as described previously 51 , using an Agilent (P/N 770995-902) 300Extend-C18, 5 μm, 250 mm × 4.6 mm id column, connected to an Agilent Technology off-line LC-system. Solvent A was 5% ACN, 10 mM NH 4 HCO 3 pH 8, and solvent B was 90% ACN, NH 4 HCO 3 pH 8. The samples were re-suspended in 500 μl solvent A and loaded onto the column. Column flow was set to 0.8 ml min −1 and the gradient length was 70 min, as follows: from 0-35 min solvent 50% A, 50% B, and from 35-50 min 100% B, and from 50-70 min 100% A. The labelled peptides were fractionated into 96 fractions, and further combined into a total of 12 fractions. Each fraction was acidified with 1% formic acid, concentrated by vacuum centrifugation to near dryness, and desalted by StageTip. Each fraction was dissolved in 5% ACN, 5% formic acid for LC-MS/MS analysis. LC-MS/MS/MS analysis. From each of the 12 fractions, approximately 3 μg was dissolved in 1% aqueous formic acid before liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis on an Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific) coupled to a Proxeon EASY-nLC 1000 liquid chromatography pump (Thermo Fisher Scientific). Peptides were fractionated on a 75-μm inner diameter microcapillary column packed with 35 cm of Accucore resin (2.6 μm, 150 Å, Thermo Fisher Scientific). For each analysis, we loaded 1 μg onto the column. Peptides were separated using a 2.5 h gradient of 2 to 25% ACN in 0.125% formic acid at a flow rate of approximately 350 nl min −1 . Each analysis used the multi-notch MS3-based TMT method 52 on an Orbitrap Fusion mass spectrometer, which has been shown to reduce ion interference compared to MS2 quantification 53 . The scan sequence began with an MS1 spectrum (Orbitrap analysis; resolution 120,000; mass range 400−1,400 m/z; automatic gain control (AGC) target 5 × 10 5 ; maximum injection time 100 ms). Precursors for MS2/MS3 analysis were selected using a Top10 method. MS2 analysis consisted of collisioninduced dissociation (quadrupole ion trap analysis; AGC 2 × 10 4 ; normalized collision energy (NCE) 35; maximum injection time 200 ms). Following acquisition of each MS2 spectrum, we collected an MS3 spectrum using our recently described method 52 in which multiple MS2 fragment ions were captured in the MS3 precursor population using isolation waveforms with multiple frequency notches. MS3 precursors were fragmented by high-energy collision-induced dissociation (HCD) and analysed using the Orbitrap (NCE 65; AGC 2 × 10 5 ; maximum injection time 300 ms, resolution was 50,000 at 400 m/z). Protein analysis. Mass spectra were processed using a Sequest-based in-house software pipeline 54 , and spectra were converted to mzXML using a modified version of ReAdW.exe. Database searching included all entries from the human Uniprot database (11 March 2014) . This database was concatenated with one consisting of all protein sequences in reverse order. Searches were performed using a 50 p.p.m. precursor ion tolerance for total protein level analysis. The product ion tolerance was set to 0.9 Da. These wide mass tolerance windows were chosen to maximize sensitivity in conjunction with Sequest searches and linear discriminant analysis 54, 55 . TMT tags on lysine residues and peptide N termini (+229.163 Da) and carbamidomethylation of cysteine residues (+57.021 Da) were set as static modifications, while oxidation of methionine residues (+15.995 Da) was set as a variable modification.
Peptide-spectrum matches (PSMs) were adjusted to a 1% FDR 56, 57 . PSM filtering was performed using a linear discriminant analysis, as described previously 54 , while considering the following parameters: XCorr, ΔCn, missed cleavages, peptide length, charge state, and precursor mass accuracy. For TMT-based reporter ion quantitation, we extracted the summed signal-to-noise (S/N) ratio for each TMT channel and found the closest matching centroid to the expected mass of the TMT reporter ion.
The search space for each reporter ion was limited to a range of 0.003 m/z to prevent overlap between the isobaric reporter ions. For protein-level comparisons, PSMs were identified, quantified and collapsed to a 1% peptide FDR and then collapsed further to a final protein-level FDR of 1%. Moreover, protein assembly was guided by principles of parsimony to produce the smallest set of proteins necessary to account for all observed peptides.
Proteins were quantified by summing reporter ion counts across all matching PSMs using in-house software, as described previously 54 . PSMs with poor quality, MS3 spectra with more than eight TMT reporter ion channels missing, MS3 spectra with TMT reporter summed signal-to-noise ratio that is less than 100, or no MS3 spectra were excluded from quantitation 58 . Protein quantification values were exported for further analysis in Microsoft Excel. Each reporter ion channel was summed across all quantified proteins and normalized assuming equal protein loading of all 11 samples. Proteomic data analysis. Quantitative analyses of protein expression were performed based on normalized TMT ratios. scRNA-seq. Pseudoislets of αGFP, αPM and βGFP cultured for 1 week were dissociated into single-cells, and single, viable and GFP + cells were sorted on a Moflo Astrios (Beckman Coulter) system. Sorted single cells from αGFP, αPM and βGFP were loaded as separated samples for single-cell RNA-seq using the Chromium Controller (10x Genomics) and the Single Cell 3′ Library Kit v2 (PN-120236, PN-120237 and PN-120262) according to the manufacturer's protocol. Amplified cDNA and subsequent libraries were assessed for quantity and quality on an Agilent 2100 Bioanalyzer (Agilent Technologies). Libraries were sequenced as 100-bp paired-end reads on a HiSeq 4000 platform (Ilumina). The Cell Ranger software pipeline (v.2.1, 10x Genomics) was used to demultiplex cellular barcodes, map reads to the transcriptome using the STAR aligner to produce a sparse cell/ gene matrix.
Further analyses were performed using the R package Seurat (v.2.3.2) 59 . As quality control steps, cells were used for analysis if they passed a total count threshold of 5,000 (αGFP), 10,000 (βGFP) or 12,000 (αPM) counts, an expressed genes threshold of 2,000 genes and had a lower percentage of mitochondrial counts than 18% (αPM and βGFP) or 20% (αGFP). Finally, cells were removed that expressed more than 100 counts of PPY. Genes were kept if they were expressed with at least 4 counts in at least 2 cells. After applying these quality control criteria, 532 single cells and 5,092 genes in total remained and were included in downstream analyses. Differential expression analysis was performed using the MAST test.
To perform pseudotime analysis of αPM cells, we used Monocle2 60 . Sparse matrix files were imported directly into Monocle using the R package cellrang-erRkit, and quality control steps were also performed in Monocle to remove low-quality cells and genes: cells were kept if they had at least 13,500 counts and 3,000 genes. Cells were removed if they expressed more than 250 counts of PPY. Genes were kept if they were expressed. To generate pseudotime trajectories, the 'DDRTree' reduction method was used in Monocle2 with the default parameters. Cells ordered in the pseudotime created 10 distinct states (Extended Data Fig. 9 ). Cells belonging to state 1 were designated as 'early αPM' , cells belonging to state 9 were designated as 'late αPM' and all other cells were designated as 'mid αPM' . Cellular identities belonging to each state were recovered from Monocle and early, mid and late αPM states were added to the corresponding cells as metadata in Seurat. Differential expression between states, αGFP and βGFP were calculated in Seurat. Immunogenicity tests. Human islets from non-diabetic donors with matching HLA class-1 A2 haplotype were obtained from ECIT or IIDP (see Supplementary  Tables 1, 2 and 22 ). FACS sorting, transduction and reaggregation were performed as mentioned above. Monotypic pseudoislets were collected 1-2 weeks after aggregation in Geneva. The pseudoislets were then taken to LUMC in Netherland to perform the CTL killing assay, as previously described 38, 39 . In brief, after dispersion with accutase, pseudoislet cells were labelled with 51 Cr and then co-cultured with the following specific CTL clones: CMVpp65 (CMV, a T-cell clone recognizing cytomegalovirus-specific antigen as negative control), alloreactive T-cell clone JS132 (HLA-A2, as positive control), INS-DRiP 1-9 (DRiP, a T-cell clone that kills stressed β-cells producing INS-DRiP 1-9 peptide, a defective ribosomal product derived from aberrant insulin transcript translation 38 ) or PPI [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] (PPI, a T-cell clone that kills β-cells presenting preproinsulin signal peptide [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] in physiological conditions. This unconventionally processed β-cell epitope is more prominently presented in hyperglycaemic conditions and T1D patients 39 ). Target cell lysis was determined by measuring 51 Cr release with γ-counter. The specificities and cytotoxic properties of CTL clones were evaluated in each independent experiment (Extended Data Fig. 10 ). In some control conditions, islet cells were loaded with either INS-DRiP 1-9 (DRiP) or PPI peptide epitopes. Animal experiments. NOD.Cg-Prkdc scid Il2rg tm1Wj /SzJ (abbreviated as NSG) mice were obtained from Charles River. NSG RIP-DTR mice were generated in the Extended Data Fig. 3 | Assessment of the effect of transcription factor expression on insulin production in human α-cells. a, Representative immunofluorescence images at 7 days of reaggregation. To determine the best α-to-β-cell reprogramming factors, human α-cells were transduced with adenoviral vectors, including PDX1, MAFA and NKX6-1, in all combinations, and then reaggregated. Images are representative of n = 38 donors for αGFP and αPM, n = 5 for αPDX1 and α3TFs, n = 3 for αMAFA, αNKX6-1, αMN6 and αPN6. b, qPCR analysis of human INS expression in α-cells transduced with indicated reprogramming factors, 7 days after aggregation. ****P < 0.0001, ***P = 0.0006 versus αGFP control, one-way ANOVA with Tukey's multiple comparisons test. n = 7 for αGFP, αPDX1, αPM and α3TFs, n = 5 for αMAFA, αNKX6-1, αMN6, αPN6: all are biological replications from different donors. c, Percentages of bihormonal cells (expressing insulin and glucagon) in αPM single cells, αPM-only pseudoislets and αPM+HM pseudoislets. One-way ANOVA with Tukey's multiple comparisons, n = 3 from different donors. d, qPCR analyses in αGFP and αPM pseudoislets cultured for 7 days. αPM cells have less glucagon expression than αGFP pseudoislets, but ARX expression is still maintained. *P = 0.015, Mann-Whitney test, two-tailed, n = 6 from different donors per group. e, qPCR analysis for INS expression in αGFP and αPM cells cultured in monolayer or pseudoislets. αPM single cells express less insulin than αPM pseudoislets; αGFP controls display only background levels. ***P = 0.0002, † † †P = 0.0009, one-way ANOVA with Tukey's multiple comparisons test, n = 4 from different donors. f, Live-cell imaging of in vitro pseudoislet formation using αPM and HM cells. Aggregation is faster with HM cells. g, Single α-cells transduced with PDX1 and MAFA show very rare reprogramming events (that is, insulin production), whereas re-aggregated α-cells display high reprogramming efficiency. α-cells (GFP + , green) locate at the periphery of pseudoislets containing also HM cells (HUVECs/MSCs: only DAPI + , white). h, Immunofluorescence for PDX1, NKX6-1 and insulin on αGFP, αPM and αPM + HM pseudoislets after 7 days of culture. Reprogrammed α-cells express insulin (red) and PDX1 (green), but not NKX6-1 (blue) in αPM and αPM + HM aggregates. i, TUNEL staining (green) reveals almost no apoptosis in α-cell pseudoislets in 7-day cultures (1.8% in αGFP, 1.4% in αPM, 1.6% in αPM + HM). j, Staining for proliferation marker pHH3 (green) reveals almost no proliferation (<1%) in both αGFP and αPM pseudoislets in 7-day cultures. Images are representative of three different donors (f-i). Data are mean ± s.e.m. Scale bars, 25 μm. Fig. 4 | γ-cell reprogramming and in vitro kinetics of cell number and gene expression levels in pseudoislets. a, Live-cell imaging during reaggregation into pseudoislets of GFP-transduced γ-cells. As in α-cell pseudoislets (Fig. 1) , sorted γ-cells were transduced with adenoviral vectors, and then seeded on reaggregation plates. b, Reprogramming efficiency into insulin expression (percentage of insulin + out of GFP + cells). Seven days after aggregation, γ-cells transduced with the indicated reprogramming factors show the highest reprogramming incidence (PM combination). *P = 0.046, ****P < 0.0001 versus γGFP control; † † †P = 0.0008 versus γPM, one-way ANOVA with Tukey's multiple comparisons test. n = 3 from different donors. c, qPCR analysis of human INS gene expression in α-cell pseudoislets. Seven days after aggregation, γ-cells transduced with the indicated reprogramming factors show the highest reprogramming incidence (PM combination). ***P = 0.0009 versus γGFP control, one-way ANOVA with Tukey's multiple comparisons test. n = 3 from different donors. Data are mean ± s.e.m. d, Immunofluorescence of γGFP and γPM pseudoislets after 7 days in culture. Most insulin-expressing reprogrammed γ-cells maintain PPY expression (blue in inset). e, Live-cell imaging of aggregated transduced γ-cells. γPM + HM pseudoislets form faster than γ-cell-only pseudoislets (a). Scale bar, 25 μm. f, g, Control γ-cells in γGFP + HM pseudoislets do not reprogram (insulin production) (<1%; left panel in f), yet PM-transduced γ-cells become insulin-producers in γPM + HM pseudoislets (right panel in f). The architecture of γPM + HM pseudoislets is similar to that of αPM + HM pseudoislets; however, γ-cell reprogramming efficiency in γPM + HM clusters is lower than in γPM-only pseudoislets (g). *P = 0.029, Mann-Whitney test, two-tailed. n = 4 from different donors. Data are mean ± s.e.m. Scale bars, 25 μm. h, Glucose-stimulated insulin secretion: γ-cells in γPM-only pseudoislets efficiently secrete insulin in response to glucose stimulation in vitro, but not γGFP pseudoislets. Notably, they secrete more insulin than α-cells in αPM + HM pseudoislets (1.24 fmol per 10 3 cells versus 0.27 fmol per 10 3 cells for converted α-cells; h and Fig. 1f ). ns, P = 0.82, **P = 0.0043, twoway repeated-measures ANOVA with Holm-Sidak's multiple comparisons test. n = 3 donor samples. Data are mean ± s.e.m. Scale bars, 25 μm. All images are representative of three (a, e) or four (d, f) independent experiments. i, DNA content was measured by Pico-green tests to assess cell number kinetics in pseudoislets in vitro. Cell numbers dropped mainly between 1 and 2 weeks in αand β-cell pseudoislets. j, Expression of human INS and adenoviral vector mouse Pdx1 and Mafa were evaluated by qPCR at indicated time points. Notably, insulin expression increased with time. Exogenous adenoviral Pdx1 and Mafa expression levels were also maintained for 8 weeks in vitro. n = 3 from different donors (i, j). Data are mean ± s.d. (i, j).
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